Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Clinical Study to Assess the Safety and Efficacy of CD70-targeted CAR-T in the Treatment of CD70-positive Refractory or Relapsed Solid Tumors

NCT06383507 is registered in ClinicalTrials.gov with Zhejiang University as lead sponsor.

NCT NCT06383507
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06383507 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Clinical Study to Assess the Safety and Efficacy of CD70-targeted CAR-T in the Treatment of CD70-positive Refractory or Relapsed Solid Tumors
Lead sponsor
Zhejiang University
Phase
Phase 1
Overall status
Not yet recruiting
Start date
April 22, 2024
Completion date
April 21, 2029
Enrollment
18 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

advanced solid tumor, cervix cancer, head and neck squamous cell carcinoma, metastatic tumor, nasopharyngeal carcinoma, ovarian cancer, renal cell carcinoma